El ciclo de los medicamentos: su impacto en el acceso y el uso adecuado

https://doi.org/10.18294/sc.2015.411

Publicado 4 marzo 2015 Open Access


Homedes Núria Médica internista, Doctora en Salud Pública. Docente, Departamento de Salud Internacional, Georgetown University; Washington DC, EE.UU , Ugalde Antonio Doctor en Derecho, Doctor en Sociología. Profesor Emérito, Departamento de Sociología, University of Texas at Austin; EE.UU




Vistas de resumen
458
Cargando métricas ...


Palabras clave:

Investigación, Vacunas, Bioética, Salud Pública, Industria Farmacéutica


Citas


1. European Federation of Pharmaceutical Industries and Associations. The Pharmaceutical Industry in Figures [Internet]. Key Data; 2014 [citado 30 jul 2014]. Disponible en: http://www.efpia.eu/uploads/Figures_2014_Final.pdf.

2. Light DW. Serious risks from new prescription drugs [Internet]. Edmond J Safra Center for Ethics, Harvard University; 27 Jun 2014 [citado 30 jul 2014]. Disponible en: http://ethics.harvard.edu/blog/new-prescription-drugs-major-health-risk-few-offsetting-advantages.

3. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the john conley lecture. JAMA Otolaryngology Head & Neck Surgery. 2014;140(12):1225-1236.

4. Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, Devine S, Druker B, Fathi A, Jabbour E, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-4442.

5. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Esptein AM. Promotion of prescription drugs to consumers. New England Journal of Medicine. 2002;346(7):498-505.

6. Boers M. Seminal pharmaceutical trials: maintaining masking in analysis. Lancet. 2002;360(9327): 100-101.

7. Lenzer J. Public interest group accuses FDA of trying to discredit whistleblower. BMJ. 2004;329 (7477):1255.

8. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021-2029.

9. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Archives of Internal Medicine. 2005;165(2):171-177.

10. Cañas M, Ugalde A, Orchuela K, Homedes N. Las secuelas del rofecoxib. Boletín Fármacos [Internet]. 2005;8(2):58-70 [citado 30 jul 2014]. Disponible en: http://www.saludyfarmacos.org/wp-content/files/apr05.pdf.